Key result
Thoracic aortic endografting yielded similar perioperative mortality and complication rates in patients ≥75 years compared to those <75 years, though female sex increased complication risk.
Why the study?
Does age ≥75 years worsen outcomes compared to age <75 years in patients undergoing thoracic aortic endografting?
Cohort (n=42)
Does age ≥75 years worsen outcomes compared to age <75 years in patients undergoing thoracic aortic endografting?
Thoracic aortic endografting can be performed safely in patients ≥75 years with comparable perioperative morbidity and mortality to younger patients.
Answers are grounded in this paper and cite their sources.
Supports comparable perioperative outcomes after thoracic aortic endografting in patients ≥75 years; leaves open confirmation via randomized trials and sex-specific risk mitigation.
OBJECTIVE: To assess the effect of age on outcomes following thoracic aortic endografting. SUMMARY BACKGROUND DATA: Endograft therapy for thoracic aortic disease is rapidly evolving. This therapy is less invasive, and elderly patients with significant medical comorbidities are more frequently referred for endografting. We hypothesized that elderly patients over the age of 75 have worse outcomes after thoracic endografting than patients under the age of 75. METHODS: We retrospectively reviewed the charts of the first 42 patients who underwent endografting for thoracic aortic pathology. Charts were reviewed for demographics, comorbid conditions, perioperative complications and death, endoleaks, and results at 3, 6, and 12 months. Preexisting medical conditions were also evaluated to determine if any patient characteristics were associated with adverse outcomes. Perioperative morbidity included cardiac, pulmonary, renal, hemorrhagic, and neurologic (stroke and spinal cord injury) complications. RESULTS: Twenty-four patients were under the age of 75, and 18 patients were 75 or older. Baseline demographics and comorbidities were similar between the 2 groups. There were no differences in operative time, length of stay, perioperative mortality, or the incidence of significant complications between the 2 age groups. Gender, however, was associated with a statistically significant difference between the occurrence of complications, with more women experiencing complications than men (P = 0.026, relative risk = 2.36). One patient (age >75 years) in the entire cohort of 42 (2.4%) suffered a spinal cord injury. At 3 months, endoleaks were more common in the older age group (P = 0.059). CONCLUSION: Endograft therapy for thoracic aortic disease can be performed safely in elderly patients with no significant increase in perioperative morbidity or mortality compared with younger patients. Female gender is associated with a higher likelihood of perioperative complications, regardless of age. The overall incidence of spinal cord injury is very low. Endograft therapy, when anatomically possible, is the treatment of choice for thoracic aortic disease in elderly patients.
No takes yet. Share an insight, caveat, or question.
Kern et al. (2006) conducted a cohort in Thoracic aortic disease (n=42). Age ≥75 years vs. Age <75 years was evaluated on Perioperative mortality and significant complications. Thoracic aortic endografting yielded similar perioperative mortality and complication rates in patients ≥75 years compared to those <75 years, though female sex increased complication risk.
Synapse has enriched 10 related papers. Consider them for comparative context: